Small Cap Feast
Small Cap Feast – 23 December 2021
Dish of the Day:
Libertine (LIB.L) has joined AIM. Libertine has developed a technology solution for powertrain OEMs, enabling efficient and clean power generation from renewable fuels. Libertine’s linear electrical machines, controls and tools together form a development platform (intelliGENTM) which the Group provides to OEM customers for their product development programmes. Mkt Cap on admission £27.6m. Capital to be raised £9m. CT Automotive Group (CTA.L) has joined AIM. CT Automotive is a UK-headquartered company that designs, develops and supplies interior components for the global automotive industry. Customers include a number of original equipment manufacturers (OEMs) and Tier One suppliers to OEMs. Mkt Cap on Admission £74.9m. Capital to be raised £33.6m. ChallengerX plc (AQSE:CXS), a “SaaS 2.0” monetisation technology and digital marketing company serving sports clubs, players, and other influencers around the world, has joined the AQSE Growth Market
Libertine (LIB.L) has joined AIM. Libertine has developed a technology solution for powertrain OEMs, enabling efficient and clean power generation from renewable fuels. Libertine’s linear electrical machines, controls and tools together form a development platform (intelliGENTM) which the Group provides to OEM customers for their product development programmes. Mkt Cap on admission £27.6m. Capital to be raised £9m.
CT Automotive Group (CTA.L) has joined AIM. CT Automotive is a UK-headquartered company that designs, develops and supplies interior components for the global automotive industry. Customers include a number of original equipment manufacturers (OEMs) and Tier One suppliers to OEMs. Mkt Cap on Admission £74.9m. Capital to be raised £33.6m.
ChallengerX plc (AQSE:CXS), a “SaaS 2.0” monetisation technology and digital marketing company serving sports clubs, players, and other influencers around the world, has joined the AQSE Growth Market
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Hybridan Small Cap Feast will be back on Tuesday 4th January 2022.
Happy Christmas to all our readers.
Graft Polymer a business focused on the development of polymer modification and drug delivery systems to join the Main Market (Standard). Graft Polymer has developed a proprietary set of polymer modification technologies, which can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing and reducing material consumption, in turn reducing costs. In late 2018, the Group began its first commercial sales to various polymer compounders in the automotive, packaging, construction, consumer products, clothing, aerospace, healthcare and medical markets. Due late Jan 2022.
Hydrogen Utopia International PLC (HUI), to join Access Segment of the Aquis Stock Exchange. The company aims to become one of the leading new European companies specialising in turning Non-Recyclable Mixed Waste Plastic into carbon-free fuels, new materials or distributed renewable heat. HUI’s activities will range across the full value chain, from the production of energy from Non-Recyclable Mixed Waste Plastic for local communities, to the sale of its products (Syngas, hydrogen, electricity and heat) to end customers. HUI’s initial strategic focus is to work closely with Powerhouse Energy Group PLC to create a project pipeline of HUI Facilities. Due 4 Jan 22. Mkt Cap TBC.
Carbon Air, a nano-technology company which leverages the adsorption properties of activated carbon and other advanced materials to improve suspension systems, enhance acoustics or reduce noise, to join AIM. The Company’s proprietary technology has allowed it to develop a unique portfolio of solutions for a variety of sizeable end markets, including vehicle suspension systems, acoustic insulation for domestic appliances and micro-speakers for smartphones. Mkt Cap and Capital to be raised TBC. Due Late Jan 2022.
i(x) Net Zero, the investing company which focusses on Energy Transition and Sustainability in the Built Environment, announces its intention to join AIM. Following Admission, the Company intends to use the net proceeds of the proposed Fundraising to provide development and expansion capital to certain of its investee companies, for future investments in companies that fall primarily within its areas of interest in Energy Transition and Sustainability in the Built Environment and to provide working capital for the Group. Capital to be raised £20m. Expected admission date Late Jan 2022.
Equinox International Holdings plc, UK-headquartered medical cannabis company aiming to become the UK’s leading ‘Land-to-Brand’ vertically integrated medical cannabis company, to seek admission of its entire share capital to trading on AIM. Seeking to raise funds to build a state-of-the-art cultivation, extraction and production facility on a Home Office-approved 20-acre UK site. Offer TBC. Due 27 Dec.
Lift Global, a financial media and technology-focused investment company led by well-known stock market commentator Zak Mir, to apply for admission of its Ordinary Shares to trading on the Access segment of Aquis Stock Exchange Growth Market. The Company plans to raise approximately £ 1.7m before expenses. First dealings in the shares are expected to commence in January 2022. The flotation is expected to value Lift at approximately £2.7m.
Superdielectrics to join AIM, a Company which is focused on developing technology to build supercapacitors with high energy density, low cost, and environmentally benign electrical energy storage devices that will help create a clean and sustainable global energy and transportation system. Admission is expected to take place in mid January 2022.
LEAF Mobile Inc. (TSX: LEAF) (OTCQB: LEMLF), a leading Canadian free-to-play mobile game group, announced its intention to join the Main Market this winter. The Company, which started trading on the Toronto Stock Exchange on February 10th, 2021, will assume a dual-listed structure. The Company intends to raise gross proceeds of approximately CAD$10m and the flotation is expected to value LEAF Mobile at approximately £130m. LEAF is operating within a fast-growing sector with a rapidly increasing total addressable market. Mobile Games are the world’s most popular form of gaming.
Spiritus Mundi due to join the Main Market (Standard), a special purpose acquisition vehicle which will seek acquisition targets in Europe and Asia in the clinical diagnostics sector. The Company has already raised approximately £1.2m in a pre-IPO fundraising round. Due Jan 2022.
Recycling Tech Group to join AIM, a UK-based engineering, research and manufacturing company that has developed a modular and mass producible machine, the RT7000, which processes hard to recycle plastic waste into a synthetic oil that can be sold back to the petrochemicals industry as a chemical feedstock to make new plastics. Targeting a £40m raise. Due early Q1 2022.
ATOME headquartered in Leeds, focussed on the large-scale production of green hydrogen and ammonia intends to join AIM. ATOME intends to be spun-out from AIM-listed President Energy Plc, an oil and gas company which has incubated and financially supported ATOME to date, by way of a dividend in specie and flotation. £6m to be raised on Admission. Anticipated Mkt Cap £26m. Due 30 Dec.
Nu-Oil and Gas to acquire Guardian Maritime Ltd and Guardian Barriers IP Ltd and become Guardian Global Security plc and join the Main Market (Standard). Guardian is a technology group that supplies products to prevent unauthorised entry into areas that are deemed to have value, with maritime security being the main focus initially. Due 24th Jan 2022.
Facilities by ADF to join AIM. Facilities by ADF plc is a provider of premium serviced production facilities to the UK film and High-end Television industry. The Group hires out its facilities to productions throughout the UK and Europe, providing its services to some of the world’s largest traditional and on-demand content production companies. The Group’s business has grown to a business servicing productions with its fleet of over 500 trailers and vehicles and providing its services to the largest global production companies including Netflix, Sky, BBC, ITV, Disney, HBO and Apple amongst others and has an estimated 35% market share of providing facilities to the UK HETV market. Anticipated Mkt Cap £37.75m. Capital to be raised £15m. Due 5 Jan 22.
Duke Royalty 43p £154.3m (DUKE.L)
The provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and North America, provided a trading update for its third financial quarter ending 31 December 2021. Having added three new Royalty Partners in Q2 FY22, Duke has continued to convert its robust pipeline in Q3 FY22, securing two additional Royalty Partners and completing three follow-on investments into existing Royalty Partners. Therefore, the Company expects that cash revenue for the quarter, being cash distributions from its Royalty Partners and cash gains from sales of equity assets, will total £3.9m. Duke is cautiously optimistic that it will be able to announce a further increase in quarterly cash revenue for the period Q4 FY22.
Fintel 227.5p £234m (FNTL.L)
Fintel 227.5p £234m (FNTL.L)
The UK fintech and support services business has announced that Premier Miton and Carmignac have joined a growing number of firms committed to multi-year agreements for its managed distribution service, launched earlier this year. This announcement follows news earlier this month of a first-of-its-kind partnership with Aviva and Aviva Investors, and deals with leading brands including Fidelity, Just, Guardian, Schroders and Tatton throughout 2021. Introduced in early 2021, Fintel’s managed distribution service is a subscription-based service that includes research, data, product design and distribution services. Delivered by SimplyBiz & Defaqto, businesses that sit within Fintel, the solution is designed to enhance the services provided to Intermediary Member Firms. SimplyBiz has also announced that Carmignac’s new range of model portfolios, as well as nine of Premier Miton’s risk-adjusted funds, will join its range of Risk Controlled investment solutions, further embedding the partnerships.
Gfinity 3.5p £38.4m (GFIN.L)
The esports and gaming solutions provider today announced an extension of its partnership with global advertising technology platform, Venatus. The renewed agreement will see Gfinity continue to benefit from the successful partnership, further accelerating its focus on driving the value per user across its fast-growing websites under the Gfinity Digital Media group (GDM). The GDM has seen significant growth across this year, now including 8 unique sites and reaching more than 15m unique users in November 2021. GDM is the foundation of Gfinity’s financial model, delivering revenues of £1.6m for the year ended 30 June 2021, up from roughly £0.3m in the previous year. Much of this growth is due to the continued improvement in the annualised value of each monthly user (MAU). Across the full year to June 2021, GDM averaged 10.7m monthly active unique users, delivering average annualised revenue of 15.2p per user. Venatus’ ability to reach and engage with gamers across a range of devices will help GDM as it focuses on its short-to-medium-term target of driving 50m MAUs at a target of 30p per MAU, which would generate revenue of £15.0m per annum.
Inspecs 370p £375m (SPEC.L)
Inspecs has completed the acquisition of Ego Eyewear Limited. Ego Eyewear is a design and licensing company and uses third party eyewear manufacturers to produce premium fashion brands. Its prestigious design house is based in Stockholm, and it also has operations in London, Osaka and Hong Kong. Ego’s licensed brands include Barbour, Liberty of London, Viktor & Rolf, Lyle & Scott, Henry Lloyd and Joseph, and Nordic brands Ivana Helsinki, Valerie and Day. Ego’s main distribution channel is through major optical chains. Inspecs Group plc has acquired 100% of Ego Eyewear Limited for an initial consideration of £6.175m and a deferred consideration partly based on performance over the next 3 years. Ego is expected to have revenue of £8.9m for the year to 31 December 2021 (2020: £3.4m), and Inspecs expects the acquisition to be earnings enhancing for 2022.
Kropz 4.75p £43.2m (KRPZ.L)
The emerging African phosphate developer announced a major milestone with the first introduction of ore to the plant at the Company’s Elandsfontein mine, located in the Western Cape in South Africa. Now that ore has been introduced to the plant, the team is ensuring all the front end circuits are balanced and running stably. The flotation circuits will then be commissioned and the reagents added in due course for the production of the first concentrate. Commissioning activities will transition into full scale ramp-up of the mining and beneficiation plant over the coming six months. Mining activities commenced in October 2021, and significant volumes of ore are available to support the commissioning ramp-up.
Physiomics* 6.65p £6.5m (PYC.L)
The consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions announced yesterday that it had been awarded a further contract by existing client Numab Therapeutics (Numab). Building on the relationship that was first announced in May this year, a second contract has now been signed relating to a further Numab programme. The project is expected to be completed in the first half of 2022. Physiomics CEO, Dr Jim Millen, commented : “We are delighted that Numab has once again chosen Physiomics as a partner to deliver insights through the use of its advanced modelling solutions.”
Plexus Holdings 8p £8m (POS.L)
The oil and gas engineering services business and owner of the proprietary POS-GRIP® friction-grip method of wellhead engineering, known for its safety, time and cost saving capabilities, has been awarded a purchase order for a POS-GRIP surface production wellhead system for a leading North Sea operator. The order includes Plexus’ POS-GRIP 10,000 psi leak proof “HG®” metal to metal sealing surface production wellhead, together with associated spares and valve equipment for a new gas well in the North Sea. The wellhead equipment is scheduled for delivery in second quarter 2022. The contract is expected to have a duration of approximately 120 days, with most of the revenue to be booked during the Company’s current 2021/22 financial year. This purchase order is in line with the Company’s IP led strategy to continue to gain market share within the production wellhead marketplace, together with the intention to move into other areas of the energy sector, including potentially, geothermal, carbon capture and hydrogen storage.
Redx Pharma 78.5p £216m (REDX.L)
The clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease today announces that a milestone payment from AstraZeneca has been triggered as a result of the initiation of a Phase 1 clinical trial of AZD5055 (RXC006), a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF). The milestone payment of $9m has been triggered under the terms of the out-licensing agreement announced on 4 August 2020 and completes the previously described potential total of $17m of early payments between deal signature and the successful commencement of the first clinical trial. Under this agreement, in addition to the $17m in early payments, Redx may receive up to a further $360m in aggregate development and commercial milestone payments. The Company is also eligible to receive tiered royalties of mid-single digit percentages, based on any future net sales.
Yourgene Health 12.75p £92.3m (YGEN.L)
The international molecular diagnostics group, announces that Yourgene Genomic Services has been awarded a contract for the provision of laboratory capacity to support the Winter Surge COVID-19 testing by the Department of Health & Social Care (DHSC), running until 31 March 2022. The ” Mini Tender Winter Surge Capacity (C47365)” contract is the third DHSC contract awarded to the Group this year under the Public Health England National Microbiology Framework Agreement. The previous two awards include the COVID-19 PCR surge testing announced on 19 August 2021 and the recent UKHSA sequencing contract announced on 14 December 2021.
Uniphar 392p £1,077.6m (UPR.L)
Uniphar plc today announces 3 acquisitions of UK-based brand commercialisation and pharmaceutical marketing agency, E4H, UK-based pharmaceutical distributor Devonshire Healthcare Services and Irish-headquartered pharmacy services group, Navi Group. E4H offers a wide range of digital and communications solutions to the pharmaceutical industry, including brand and strategy commercialisation, digital development, omnichannel delivery, engagement and data analysis. Devonshire has provided access to unlicensed and difficult to source medicines across the Middle East and North Africa region for 25 years to a broad variety of healthcare authorities, hospitals, overseas ministries of health and military agencies. Navi drives innovation within the Irish pharmacy sector through leading digital platforms and consistent supply of quality pharmaceutical products to its Irish and MENA partners. Each acquisition includes an upfront payment plus contingent consideration payable upon achievement of certain financial hurdles and each are expected to deliver a Return on Capital Employed to the Group in line with Uniphar’s target rate of 12%-15% within three years. The combined revenue of the acquisitions is EUR39m with the total increase in the number of colleagues joining Uniphar being 110 and expected annualised earnings accretion of mid-single digit.
Emily Liu, CFA, CAIA
0203 764 2344
0203 764 2345
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.